SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Submission of Matters to a Vote of Security Holders
ITEM5.07.Submission of Matters to a Vote of Security
Holders
The 2017 Annual Meeting of Stockholders of Second Sight Medical
Products Inc. (Second Sight or Company) was held on June 6, 2017
in Sylmar, California. Holders of 43,449,144 shares of Second
Sight’s common stock were represented at the meeting in person
or by proxy, constituting a quorum. The following are the voting
results on each matter submitted to the stockholders of Second
Sight at the annual meeting. The proposals acted upon by the
stockholders are described in detail in Second Sight’s Proxy
Statement which was filed with the Securities and Exchange
Commission on May 1, 2017.
Proposal 1: The stockholders elected each of the six
director nominees to the Board of Directors of the Company to
serve until the 2018 Annual Meeting of Stockholders and until his
successor has been duly elected and qualified, as follows:
| Nominee | For | Against | Abstentions |
Broker Non-Votes |
||||
| Will McGuire | 27,745,308 | 560,410 | 48,424 | 15,095,002 | ||||
| Robert J. Greenberg | 27,694,923 | 554,050 | 105,169 | 15,095,002 | ||||
| William J. Link | 27,585,578 | 267,095 | 501,469 | 15,095,002 | ||||
| Aaron Mendelsohn | 27,894,631 | 321,928 | 137,583 | 15,095,002 | ||||
| Gregg Williams | 27,408,723 | 590,146 | 355,273 | 15,095,002 | ||||
| Matthew Pfeffer | 27,904,410 | 251,975 | 197,757 | 15,095,002 |
Proposal 2: The stockholders approved an amendment to the
2011 Equity Incentive Plan (Plan) to increase the maximum number
of shares of common stock that may be issued under the Plan from
7,500,000 shares to 9,500,000 shares, as follows:
| For | Against | Abstentions |
Broker Non-Votes |
|||||
| 26,715,567 | 1,563,129 | 75,446 | 15,095,002 |
Proposal 3: The stockholders approved an amendment to
Second Sight’s 2015 Employee Stock Purchase Plan to increase the
maximum stated number of shares of common stock which may be
issued under the plan from 250,000 shares to 750,000 shares, as
follows:
| For | Against | Abstentions |
Broker Non-Votes |
|||||
| 27,322,058 | 961,834 | 70,250 | 15,095,002 |
Proposal 4: The stockholders ratified the appointment of
Gumbiner Savett Inc. as Second Sights independent registered
public accounting firm for the year ending December 31, 2017, as
follows:
| For | Against | Abstentions |
Broker Non-Votes |
|||||
| 42,318,926 | 517,560 | 612,658 |
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.
